SCHEMBL8023076

SCHEMBL8023076

CCOc1ccc(S(=O)(=O)N(Cc2ccccc2N)C(CO)C(=O)OC)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 3/20 0.46
NFE2L2 Q16236 1/20 0.46
POLB P06746 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 3/20 0.41
MMP13 P45452 5/20 0.41
MMP8 P22894 4/20 0.41
MMP1 P03956 3/20 0.41
MMP7 P09237 1/20 0.41
MMP12 P39900 1/20 0.41
MMP2 P08253 3/20 0.41
MMP9 P14780 3/20 0.41
BMP1 P13497 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41
ADAM17 P78536 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5655796 0.91 KEAP1 (0.56) KEAP1NFE2L2MMP13MMP8MMP1
SCHEMBL7389789 0.86 KEAP1 (0.44) KEAP1NFE2L2MMP13MMP8MMP1
SCHEMBL6608765 0.81 KEAP1 (0.64) KEAP1NFE2L2MMP13MMP8MMP1
SCHEMBL6610164 0.79 BMP1 (0.48) KEAP1NFE2L2MMP13MMP8MMP1
SCHEMBL6609943 0.77 MMP1 (0.47) KEAP1NFE2L2MAPTMMP13MMP8
SCHEMBL6612548 0.76 ADAM17 (0.44) MMP13MMP8MMP1MMP7MMP2
SCHEMBL5654237 0.76 MMP1 (0.69) KEAP1NFE2L2MMP13MMP8MMP1
SCHEMBL6613444 0.76 KEAP1 (0.53) KEAP1NFE2L2KMT2AMMP13MMP8
SCHEMBL6609503 0.74 BMP1 (0.52) KEAP1NFE2L2POLBKMT2AMMP13
Anisole SCHEMBL27490678 0.73 KEAP1 (0.40) KEAP1NFE2L2MMP13MMP8MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6071903-A ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-06-06 US disclosed